InvestorsHub Logo
Post# of 252263
Next 10
Followers 834
Posts 119875
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 240290

Monday, 02/28/2022 10:00:34 AM

Monday, February 28, 2022 10:00:34 AM

Post# of 252263
VTRS sells JV stake in Humira/Enbrel/Eylea-biosimilars portfolio_to Biocon for $3B plus contingencies…

4Q21 results:
https://investor.viatris.com/news-releases/news-release-details/viatris-reports-strong-fourth-quarter-and-full-year-2021

CC slides:
https://investor.viatris.com/static-files/6a055dc2-4cd2-4d6c-91c9-c426ec1dcbce

Note: VTRS is retaining its participation in the Botox-biosimilar program with RVNC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.